Accelerating Breakthrough Discoveries into Medicines



Allinaire Awarded Grant for Novel Pulmonary Treatment

Allinaire awarded grant for novel pulmonary treatment

CLEVELAND and INDIANAPOLIS, February 12, 2018 – Allinaire Therapeutics has been awarded a Phase I Small Business Technology Transfer grant from the National Heart, Lung and Blood Institute in the amount of $281,155. This funding will support the development of a novel therapeutic for the treatment of viral-associated lung injury. Allinaire’s aim is to develop new drug therapies for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.

“This grant allows Allinaire to advance the application of its technology in other pulmonary indications and elevate its opportunity to develop better therapies for patients,” said Baiju R. Shah, CEO of BioMotiv and Chairman of the Allinaire Board.

In 2016, Allinaire was formed by BioMotiv, the for-profit drug development accelerator associated with the Harrington Project for Discovery & Development, Indiana University Research & Technology Corp (IURTC), BioCrossroads, and Innovate Indiana. In addition, Allinaire has received several grant awards to support development of its technologies from the Department of Defense and the National Institutes of Health.

About Allinaire

Allinaire Therapeutics aims to develop novel therapeutics for COPD and other pulmonary diseases. The technology is based on the discovery by the scientific founders, Irina Petrache, MD, and Matthias Clauss, PhD, of a novel therapeutic target that plays a central role in the development and progression of lung disease and is licensed exclusively from Indiana University. Learn more at

About BioMotiv

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of drug development programs. Learn more at:

Erin Reese